Clinical Trial Goal
To find out:
- The highest dose of SIM0500 that's safe to give
- If SIM0500 is safe and works well to treat multiple myeloma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that has relapsed or is refractory
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
SIM0500 is a tri-specific antibody that targets BCMA, CD3 and GPRC5D in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- SIM0500 – Given as a shot under your skin. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working.
The Food and Drug Administration (FDA) has not yet approved SIM50500.
Contacts
Study Contact, 8573330740, clinicaltrials@simceregroup.com
Wenjuan Wang, wangwenjuan4@simceregroup.com
Locations
Sponsors
collaborator: Shanghai Xianxiang Medical Technology Co., Ltd., lead: Jiangsu Simcere Pharmaceutical Co., Ltd.
